Literature DB >> 23683260

Risk factors for acute kidney injury in the elderly undergoing contrast-enhanced computed tomography in the emergency department.

Ming-Kun Huang1, Teh-Fu Hsu, Yu-Hui Chiu, Shu-Chiung Chiang, Wei-Fong Kao, David Hung-Tsang Yen, Mu-Shun Huang.   

Abstract

BACKGROUND: There have been few studies focusing on the incidence and risk factors for elderly patients undergoing computed tomography (CT) scans with intravascular contrast medium, who develop contrast-induced nephropathy (CIN) in the emergency department (ED). Our objective was to investigate the incidence of and risk factors for, CIN in elderly patients seen in the ED, who receive intravenous contrast media for CT examination.
METHODS: Patients ≥65 years of age who received contrast-enhanced CT were eligible for inclusion in this retrospective analysis. CIN was defined as an increase in serum creatinine (sCr) ≥0.5 mg/dL 48 to 72 hours after intravenous contrast administration. Multiple logistic regression analysis for risk factors for CIN and Chi-square test were performed for trend analysis for CIN incidence and mortality of different risk scores.
RESULTS: A total of 594 patients, with a mean age of 79.8 ± 6.8 years were included. The overall incidence of CIN was 8.6%. In multivariate analyses, CIN was associated with diabetes mellitus [adjusted odds ratio (OR) = 1.93; 95% confidence interval (CI) = 1.04-3.62], precontrast sCr >1.5 mg/dL (OR = 2.72; 95% CI = 1.44-5.13), and acute hypotension (OR = 3.56; 95% CI = 1.29-9.84). CIN and mortality increased with increasing risk score (p < 0.001 and p = 0.001, respectively). The all-cause in-hospital mortality rate was 13.1%, and the mortality rates for patients with and without CIN (p < 0.001) were 47.1% and 9.9%, respectively.
CONCLUSION: Our investigation confirmed diabetes mellitus, precontrast sCr >1.5 mg/dL and acute hypotension as risk factors for CIN, and also developed a simple risk score for elderly patients seen in the ED.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23683260     DOI: 10.1016/j.jcma.2013.01.007

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  11 in total

1.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Clin Exp Nephrol       Date:  2020-01       Impact factor: 2.801

2.  Systematic unenhanced CT for acute abdominal symptoms in the elderly patients improves both emergency department diagnosis and prompt clinical management.

Authors:  Ingrid Millet; Mustapha Sebbane; Nicolas Molinari; Emma Pages-Bouic; Fernanda Curros-Doyon; Bruno Riou; Patrice Taourel
Journal:  Eur Radiol       Date:  2016-06-07       Impact factor: 5.315

3.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Jpn J Radiol       Date:  2020-01       Impact factor: 2.374

Review 4.  The Incidence and Associated Risk Factors of Contrast-Induced Nephropathy after Contrast-Enhanced Computed Tomography in the Emergency Setting: A Systematic Review.

Authors:  Mei-Yi Ong; Justin Jie-Hui Koh; Suchart Kothan; Christopher Lai
Journal:  Life (Basel)       Date:  2022-06-01

5.  Incidence and risk of developing contrast-induced acute kidney injury following intravascular contrast administration in elderly patients.

Authors:  Wei Song; Tuo Zhang; Jun Pu; Linghong Shen; Ben He
Journal:  Clin Interv Aging       Date:  2013-12-31       Impact factor: 4.458

Review 6.  ACE-I/ARB therapy prior to contrast exposure: what should the clinician do?

Authors:  Robert Kalyesubula; Peace Bagasha; Mark A Perazella
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

7.  Trends of CT utilisation in an emergency department in Taiwan: a 5-year retrospective study.

Authors:  Sung-Yuan Hu; Ming-Shun Hsieh; Meng-Yu Lin; Chiann-Yi Hsu; Tzu-Chieh Lin; Chorng-Kuang How; Chen-Yu Wang; Jeffrey Che-Hung Tsai; Yu-Hui Wu; Yan-Zin Chang
Journal:  BMJ Open       Date:  2016-06-08       Impact factor: 2.692

Review 8.  Radiographic and magnetic resonances contrast agents: Essentials and tips for safe practices.

Authors:  Mohamed R Nouh; Mohamed A El-Shazly
Journal:  World J Radiol       Date:  2017-09-28

9.  Epidemiology and outcomes of acute kidney injury in elderly chinese patients: a subgroup analysis from the EACH study.

Authors:  Shuwang Ge; Sheng Nie; Zhangsuo Liu; Chunbo Chen; Yan Zha; Jing Qian; Bicheng Liu; Siyuan Teng; Anping Xu; Wei Bin; Xin Xu; Gang Xu
Journal:  BMC Nephrol       Date:  2016-09-29       Impact factor: 2.388

10.  Risk of renal events following intravenous iodinated contrast material administration among inpatients admitted with cancer a retrospective hospital claims analysis.

Authors:  Chaan S Ng; Sanjeeva P Kalva; Candace Gunnarsson; Michael P Ryan; Erin R Baker; Ravindra L Mehta
Journal:  Cancer Imaging       Date:  2018-08-24       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.